Introduction
============

Daptomycin, a cyclic lipopeptide antibiotic, is one of the last-line agents for the treatment of certain severe multidrug-resistant *Staphylococcus aureus* infections, including those caused by methicillin-resistant *S. aureus* (MRSA) ([@B19]). Daptomycin functions by inserting itself into the bacterial cell membrane in a calcium-dependent manner to cause membrane depolarization, leading to cell death ([@B19]; [@B2]). Daptomycin-nonsusceptible (DAP-NS) MRSA isolates, although still uncommon, have emerged during daptomycin treatment of patients ([@B34]; [@B5]). DAP-NS MRSA mutants have also been generated in the laboratory by serial passage of isolates in sublethal concentrations of daptomycin ([@B19]; [@B6]; [@B42], [@B41]; [@B53]).

The exact mechanisms giving rise to daptomycin-non-susceptibility in *S. aureus* are not fully elucidated but appear to involve diverse genetic events and several genetic loci, including *mprF*, *yycG* (*walK*), *vraSR*, *tagA*, and *dltABCD* ([@B23]; [@B2]; [@B3]; [@B56]). These loci are all part of the cell wall stimulon in *S. aureus* and include genes encoding proteins involved in the production of membrane phospholipids. The *mprF* (multiple peptide resistance factor) gene seems to be especially critical, as *mprF* mutations are the most frequently reported genetic lesions in DAP-NS MRSA isolates ([@B23]; [@B34]; [@B5]; [@B39]). MprF is a bi-functional membrane protein with lysylphosphatidylglycerol (LPG) synthase and flippase activities ([@B50]; [@B21]; [@B20]). Different point mutations in *mprF* have been associated with elevated LPG synthesis. This results in increased amounts of LPG relative to phosphatidylglycerol (PG) on the outer leaflet of the cytoplasmic membrane and an accompanying reduction in cell membrane negative charge ([@B2]; [@B53]).

A feature that has been seen in both clinical and laboratory-generated DAP-NS MRSA isolates is a concomitant vancomycin intermediate or heterogeneous intermediate resistance (VISA or hVISA) phenotype ([@B6]; [@B42]); VISA has moderate resistance to vancomycin and hVISA has varying sub-population of cells resistant to vancomycin, thus exhibit mixed susceptibility to vancomycin. Mutations in the *vraSR*, *graSR*, or *walKR* (*yycGF*) two-component systems have been associated with the VISA/hVISA phenotype ([@B28]). Among these 3 two-component systems, the VraSR system is particularly important in maintaining cell wall integrity. It serves as a sentinel in response to cell wall damage by positively regulating a unique set of genes involved in cell wall synthesis, resulting in the generation of a resistant phenotype ([@B32]; [@B24]; [@B37]). Another unusual feature is the so-called "seesaw" effect on β-lactam susceptibility, wherein DAP-NS isolates exhibit reduced β-lactam MICs ([@B42]; [@B34]; [@B60]; [@B39]). However, these phenomena are not observed in all DAP-NS MRSA isolates.

Our previous study of eight sequential clinical MRSA isolates from a patient with persistent bacteremia revealed an L431F amino acid substitution in the MprF protein of DAP-NS isolates ([@B34]). Since this mutation had not been reported previously, we undertook the present study to determine the effect of this mutation on the cellular response to daptomycin. To eliminate the possibility of unknown genetic changes that might have occurred in paired clinical strains, we used a base-substitution method to replace a single nucleotide (from CTT to TTT) within the chromosomal *mprF* gene of the daptomycin-susceptible (DAP-S) progenitor of the DAP-NS strains. To confirm the results obtained by this single amino acid exchange (L431F) in MprF, we also constructed a reverse mutant carrying F431L MprF as well as a silent EcoRV site. Our study demonstrated that this single amino acid change (L431F) confers increased resistance to both daptomycin and vancomycin, with a concurrent decrease in oxacillin MIC. The phenotype and genetic factors associated with these changes were investigated.

Materials and Methods {#s1}
=====================

Bacterial Strains
-----------------

The bacterial strains, plasmids, and primers used are listed in **Tables [1](#T1){ref-type="table"}**, **[2](#T2){ref-type="table"}**. Unless stated otherwise, Luria-Bertani (LB) broth and plates were used for growth of *Escherichia coli* and *S. aureus* at 37°C. *E. coli* strain XL10-Gold (Stratagene, La Jolla, CA, United States) and GeneHogs^®^ (Invitrogen, Carlsbad, CA, United States) were used for cloning. *S. aureus* cells were transformed by electroporation, as described previously ([@B54]). Ampicillin (100 μg/ml), chloramphenicol (5 μg/ml), erythromycin (5 μg/ml), spectinomycin (100 μg/ml), and tetracycline (5 μg/ml) were used for plasmid selection in *E. coli* and *S. aureus*.

###### 

Bacterial strains and plasmids used in this study.

  Strain/plasmid        Description                                                                                                                                                      Source or Reference
  --------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------
  **Strains**                                                                                                                                                                            
     *E. coli*                                                                                                                                                                           
       XL10-Gold        Ultra-competent cell for site-directed mutagenesis                                                                                                               Stratagene
       Genehogs         Electrocompetent cells                                                                                                                                           Invitrogen
     *S. aureus*                                                                                                                                                                         
       RN4220           Restriction-deficient derivative of 8325-4                                                                                                                       [@B46]
       RN6911           RN6390B *agr*::*tetM* (*agr*-null)                                                                                                                               [@B47]
       Z172             Clinical VISA isolate with *spc* gene                                                                                                                            [@B8]
       CGK5             Daptomycin-susceptible MRSA                                                                                                                                      [@B34]
       CGK5mut          MprF L431F derivative of CGK5                                                                                                                                    This study
       CGK5mutR         Reversed derivative of CGK5mut with MprF containing F431L and a new EcoRV site                                                                                   This study
       CGK6             Daptomycin-non-susceptible MRSA                                                                                                                                  [@B34]
     *E. faecium*                                                                                                                                                                        
       2V076            Clinical isolate with *aadE*-*sat4*-*aphA*-3 gene cluster                                                                                                        This study
  **Plasmids**                                                                                                                                                                           
       pMAD             pE194^ts^ derivative for gene replacement in Gram-positive bacteria                                                                                              [@B1]
       pMAD-SAT4-tetM   Modified pMAD with *sat4* and *tetM* markers                                                                                                                     This study
       pMprFmut         The *mprF* fragment amplified from CGK6 and cloned into pMAD-SAT4-tetM for allelic exchange in CGK5                                                              This study
       pMprF5           The *mprF* fragment amplified from CGK5 and cloned into pMAD-SAT4-tetM for site-directed mutagenesis                                                             This study
       pMprFmutR        A silent EcoRV site was introduced into the middle of the *mprF* fragment amplified from pMprF5 and cloned into pMAD-SAT4-tetM for allelic exchange in CGK5mut   This study
       pluxT2           pSK5630 derivative containing *luxABCDE* with T2 terminator                                                                                                      [@B9]
       pluxT2-SPC       pluxT2 with *spc* marker                                                                                                                                         This study

ts

Stands for thermosensitive.

###### 

Primers used in this study.

  Primers                                           Nucleotide sequence (5′--3′)^a^
  ------------------------------------------------- -----------------------------------------------------------------------------------------
  **Cloning of new pMAD**                           
  *bgaB*new-F                                       CG[GGATCC]{.ul}AG[GAATTC]{.ul}GCT[CCCGGG]{.ul}CATG[CCATGG]{.ul}GTCTAGTTAATGTGTAACGTAACA
  *bgaB*new-R                                       ACGC[GTCGAC]{.ul}GTA[AGGCCT]{.ul}TCACTAAACCTTCCCGGCTTC
  *sat4*-F                                          P-AGAGAGGCGGGAACAGTG
  *sat4*-R                                          ACGC[GTCGAC]{.ul}TGC[AGGCCT]{.ul}TC[AGATCT]{.ul}AAGACGAACTCCAATTCACT
  *tetM*-F                                          P-GGAGATTCCTTTACAAATATG
  *tetM*-R                                          ACGC[GTCGAC]{.ul}GTA[AGGCCT]{.ul}ATAACAACATAAAACGCACTA
  **Cloning of *mprF* gene for allelic exchange**   
  *mprF*-F                                          CG[GGATCC]{.ul}TAGAATTGATGTGAAAAAATGA
  *mprF*-R                                          TCC[CCCGGG]{.ul}CGCATCAGGCATAACTGTATA
  **Site-directed mutagenesis**                     
  *mprF*(EcoRV)-F                                   P-[AT]{.ul}**[C]{.ul}**ATTGCTAAAATTCCATCATTGTC
  *mprF*(EcoRV)-R                                   [ATC]{.ul}CTTTTGATAAGACATTAAAA
  **Real-time qPCR**                                
  *mprF*-QF                                         TCATTATTGCTGCATTATCTGGA
  *mprF*-QR                                         TTTTCCTCAGGGACACCTAAAG
  *vraSR*-QF                                        GCCAGATTCAGGTACACG
  *vraSR*-QR                                        TCTGAGTCGTCGCTTC
  *fmtA*-QF                                         AAAACATCTAAGCCTATCCCATTG
  *fmtA*-QR                                         TTTGAATCGCTTTAACTGCTTGAT
  *murZ*-QF                                         AAAATAAGAGGTGGACGCACA
  *murZ*-QR                                         ACTGTTTTTCGCGCCACT
  *pbp2*-QF                                         TCGGTGCAATTGGTAAGAACT
  *pbp2*-QR                                         TTAATGTTGAGGCACCTTCAGA
  *sgtB*-QF                                         TAGCGACAGAGATGTGC
  *sgtB*-QR                                         TTGTGACATAGCCTGTTG
  *tagA*-QF                                         AATAAATCAAGCGAGCTATATTGTTG
  *tagA*-QR                                         ACGATGCGAAGCTTTGACTAC
  *gyrB*-QF                                         CGTTAATTGAAGCAGGCTATGTG
  *gyrB*-QR                                         TGGTGTTGGATTCAATTCAGATT
  **Cloning of promoter-reporter**                  
  *spc*-F                                           P-AAAGTTCTCGTTCGGAGG
  *spc*-R                                           TCC[CCCGGG]{.ul}AAAGTAAGCACCTGTTATTGC
  P*mprF*-F                                         CG[GGATCC]{.ul}GAAAATAAAAACAAGTGGTAT
  P*mprF*-R                                         ACGC[GTCGAC]{.ul}TTAACTTCCTGATTCATTT
  P*vraSR*-F                                        CG[GGATCC]{.ul}CGTTTATCTCATCAAATG
  P*vraSR*-R                                        ACGC[GTCGAC]{.ul}TAGTTCATAACTATCACCTTT

a

Restriction enzyme sites are underlined. P represents phosphorylation. Boldface type indicates a mutant nucleotide.

Construction of MprF Mutant Derivatives
---------------------------------------

To add new selection markers and cloning sites, the *bgaB* cassette located between the HindIII sites was removed from pMAD by digesting with HindIII, and religated. A modified *bgaB*, with extra restriction sites, was cloned by PCR (using primers *bgaBnew*-F and *bgaBnew*-R) from the original pMAD into the pMAD lacking the *bgaB* cassette to generate new pMAD. Two selection markers, as *sat4* and *tetM* cassettes, were incorporated by cloning PCR fragments of the *sat4* and *tetM* genes from the chromosomal DNA of 2V076 and RN6911, respectively, into the StuI-SalI sites of the new pMAD using primers *sat4*-F and *sat4*-R, and *tetM*-F and *tetM*-R to produce pMAD-SAT4-tetM, which confers resistance to nourseothricin and tetracycline. To assess the effect of MprF L431F on daptomycin non-susceptibility, an *mprF*-bearing fragment from CGK6 (the first DAP-NS isolate containing the MprF F431 mutant) was amplified by PCR using the primers *mprF*-F and *mprF*-R, and ligated into the BamHI-SmaI sites of pMAD-SAT4-tetM. This recombinant plasmid, pMprFmut, was used as the allelic exchange vector for mutation of the *mprF* gene in CGK5 to create CGK5mut. To validate the phenotypes in CGK5mut, the mutant strain was reverted to wild type by allelic exchange again. The *mprF* fragment was amplified from CGK5 and then cloned into pMAD-SAT4-tetM. This recombinant plasmid, pMprF5, was used as the template DNA for site-directed mutagenesis to introduce a new EcoRV site^[1](#fn01){ref-type="fn"}^ into the complementation construct (and without altering the coding sequence) to allow it to be differentiated from the CGK5 parental strain. After PCR using the mutant primers *mprF*(EcoRV)-F and *mprF*(EcoRV)-R, the *mprF* reverse mutant was treated with DpnI, ligated into a circle with T4 DNA ligase, and then used as the template DNA. The entire *mprF* gene was then cloned from the mutated plasmid into the pMAD-SAT4-tetM vector again to eliminate potential mutation of the vector sequence. The constructs were verified by restriction analysis and DNA sequencing. Sequencing was performed at the DNA Sequencing Core Lab of our institutes.

The allele replacement procedure was applied to create a single base replacement in the *mprF* gene of CGK5, as described previously ([@B1]). Briefly, the pMprFmut plasmid was electroporated into *S. aureus* strain RN4220, and then electroporated into CGK5. Transformants were selected at 30°C on LB plates containing tetracycline and X-Gal (150 μg/ml). One blue colony was inoculated in Trypticase Soy broth (TSB) containing tetracycline and incubated with shaking for 2 h at 30°C followed by 6 h at 43°C, serial diluted then plated on Trypticase Soy agar (TSA) plates containing tetracycline and X-Gal and incubated at 43°C overnight to obtain light blue colonies caused by a single crossover event. One light blue colony was inoculated in TSB without antibiotic and incubated with shaking at 30°C overnight, then diluted 1:100 and incubated at 43°C for 6 h; serial dilutions were plated on TSA plates in the absence of antibiotics and incubated at 37°C overnight. Several white colonies were selected to verify for tetracycline sensitivity, which indicates loss of the integrated vector resulting from a double crossover event. To confirm the double crossover, PCR amplifications were performed with multiplex primers hybridizing outside and inside of the *mprF* gene and vector sequences. A colony with a single crossover was used as a negative control. The resulting mutant was verified by DNA sequencing, including the adjacent region of the *mprF* gene. The complementation construct (CGK5mutR) was constructed by the same procedure.

Antimicrobial Susceptibility Testing
------------------------------------

The MICs of daptomycin, oxacillin and vancomycin were determined by Etest^®^ (bioMérieux SA, Marcy l'Étoile, France) following the manufacturer's instructions and using Mueller Hinton II agar (MHA) (Becton Dickinson, Cockeysville, MD, United States). The daptomycin Etest strips were overlaid with 40 μg/ml of calcium (Package insert) and the MHA contained 2.9--5.9 μg/ml of calcium. The MICs of oxacillin were also determined by broth microdilution (BMD) ([@B11]). The BMD method was performed in Mueller Hinton II broth (MHB) (Becton Dickinson) with and without 2% NaCl from an inoculum of 5 × 10^5^ CFU/ml, and the MIC was read after incubation at 35°C for 24 h. *S. aureus* ATCC 29213 and *Enterococcus faecalis* ATCC 29212 were used as quality control organisms for Etest. *S. aureus* ATCC 29213 and ATCC 43300 were used as quality control organisms for BMD.

Population Analysis Profiles
----------------------------

A population analysis profile (PAP) for vancomycin was performed on CGK5 and CGK5 mutant derivatives following protocols previously described ([@B26]; [@B29]). Briefly, overnight cultures of test isolates were serially diluted in TSB and inoculated onto brain--heart infusion (BHI) agar plates containing 0--8 μg/ml vancomycin. After 48 h incubation at 35°C, colonies were counted and plotted. Mu3 (ATCC 700698) and N315 *S. aureus* strains were tested in parallel as hVISA positive and negative controls, respectively. The area under the curve (AUC) values of the test strains were compared to that of Mu3.

Cell Wall Thickness
-------------------

Bacterial cells for transmission electron microscopy were prepared following previously described protocols ([@B25]). Photographic images were obtained at a final magnification of 15,000× using a Hitachi H-7650 microscope (Hitachi High-Technologies Corporation, Tokyo, Japan). Fifty measurements of equatorially cut cells were taken for the calculation of cell wall thickness, and results were expressed as mean ± SD following previously described protocols ([@B14]).

Growth Rate
-----------

Overnight fresh cultures of bacteria were adjusted in 0.85% NaCl to 0.5 McFarland turbidity, then diluted 1:200 in MHB to obtain 5 × 10^5^ CFU/ml starting inoculum. The inoculum was dispensed at 120 μl per well in triplicates into a 100-well plate and incubated at 37°C in Bioscreen C MBR (Oy Growth Curves Ab Ltd, Helsinki, Poland) ([@B52]). Triplicate medium-only blank wells were included in each plate. The OD~600~ of each well was read every 30 min for 24 h. The average OD of the blank wells was subtracted from the average of the triplicate test wells at each time point and plotted. Doubling times were calculated using the exponential growth phase following a previously described protocol ([@B13]). To verify the OD measurements, the CFU counts were checked by the shaker flask method.

Cytochrome *c* Binding Assay
----------------------------

Cytochrome *c* binding assay was performed following an approach similar to that of [@B43] with slight modification. Briefly, bacteria grown overnight at 35°C were harvested and washed twice with 20 mM MOPS buffer (pH 7.0) and resuspended in the same buffer to a final OD~578~ of 7. Cytochrome *c* (Sigma Chemicals, St. Louis, MO, United States) was prepared in the same buffer. The bacterial suspension was incubated with 1 mg/ml cytochrome *c* for 10 min, and then centrifuged at 3000 *g* at 4°C for 10 min. The supernatant containing unbound cytochrome *c* was collected and measured spectrophotometrically at OD~530~. The cytochrome *c* was serially diluted (0.1--0.6 mg/ml) to create a standard curve to measure the cytochrome *c* concentration of the supernatant.

Western Blot Analysis for PBP2a Detection
-----------------------------------------

Detailed descriptions of mouse monoclonal anti-PBP2a antibody (2F6F) production and detection of PBP2a were presented previously ([@B9]). However, in that study, PBP2a was detected in the total protein preparation. In the present study, for more precise detection of PBP2a in the membrane, membrane fraction was prepared following previously described protocol with slight modifications ([@B17]). Briefly, strains were grown in TSB overnight at 37°C with shaking at 200 rpm, then diluted 1/100 in 50 ml fresh medium and further incubated until cells reached an OD~600~ of 1. Ten milliliter of the bacterial cultures was then centrifuged, and the pellet was resuspended in 1 ml lysis buffer. Cells were disrupted by FastProtein^TM^ Blue Matrix using a FastPrep-24 homogenizer (MP Biomedicals) at 6 M/s for 4 cycles of 20 s with a 2-min ice incubation in between each cycle. Protein samples (1 μg of protein per lane) were separated in 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and then transferred to a polyvinylidene difluoride membrane (Immobilon, Millipore Corp., Bedford, MA, United States). PBP2a was probed with mouse monoclonal anti-PBP2a antibody (2F6F), and bands were visualized with HRP-conjugated secondary antibodies (Abcam Inc., Cambridge, MA, United States) followed by incubation in Western lightning chemiluminescence reagent plus (Perkin Elmer Life Sciences, Boston, MA, United States). Sortase A, a transpeptidase, was used as an internal control, identified by rabbit polyclonal anti-Sortase A primary antibody (Abcam Inc.).

Real-Time Quantitative PCR Analysis for *mprF*, *vraSR*, and Cell Wall Synthesis-Related Genes
----------------------------------------------------------------------------------------------

For RNA isolation, strains were grown overnight with shaking at 37°C in MHB and diluted with 5 ml fresh medium to 1/100. They were then grown at 37°C with shaking at 200 rpm, and samples were collected from four time points (2, 3, 4, 5 h) for analysis. Approximately 2 × 10^9^ cells were harvested for RNA isolation. Total RNA isolation was performed as described previously ([@B10]). Real-time quantitative PCR analysis was performed using Maxima SYBR Green qPCR Master Mix (Thermo Fisher Scientific, United States) on a Roche LightCycler 480 II Real-Time PCR System (Roche). Results were normalized to the expression of *gyrB*. The expression levels of *mprF*, *vraSR*, and several selected cell wall synthesis-related genes (*fmtA*, *murZ*, *pbp2*, *sgtB*, *tagA*) were determined using the primers listed in **Table [2](#T2){ref-type="table"}**. The expression of *ldh1*, a gene involved in nitric oxide resistance in *S. aureus* ([@B52]), was used as a negative control. The target gene transcripts were quantified by using the basic relative quantification method of the LightCycler 480 Software v1.5.1.62 (Roche). Three independent experiments were performed in duplicate and results are shown as mean ± SD. The mRNA expression levels of genes from CGK5 were defined as 1.

Construction of *mprF* and *vraSR* Promoter-Reporter Plasmids
-------------------------------------------------------------

For introducing the pluxT2 reporter into CGK5, the selection marker *spc* was amplified by PCR from the Z172 strain ([@B8]), digested with SmaI and then cloned into pluxT2 ([@B9]) to generate pluxT2-SPC. The *mprF* and *vraSR* promoter fragments were PCR-amplified from the chromosome of CGK5 using the primers P*mprF*-F, P*mprF*-R and P*vraSR*-F, P*vraSR*-R. These amplified promoter fragments were fused upstream of the *lux* reporter genes of pluxT2-SPC using the BamHI and SalI sites, and the resulting plasmids were used for transformation of the *S. aureus* strain RN4220 and then of CGK5 and CGK5 mutant derivatives. The resulting promoter-reporter fusion constructs were confirmed by restriction enzyme analysis and DNA sequencing.

Luciferase Reporter Assays
--------------------------

Bioluminescence was measured with a SpectraMax L microplate reader (Molecular Devices, Sunnyvale, CA, United States) to determine the transcriptional level of the *mprF* and *vraSR* promoter constructs. Three independent transformants harboring promoter-reporter fusion plasmids were grown overnight with shaking at 37°C in TSB containing spectinomycin for reporter plasmid maintenance, diluted 1:100 in the same medium, and aliquots (200 μl) of the cultures were transferred into 96-well plates in duplicate and incubated at 37°C. Both OD~595~ and bioluminescence (in relative light units, RLU) were monitored every hour for 7 h.

Statistical Analysis
--------------------

Assay results are reported as mean ± SD where appropriate. For comparison of differences between CGK5 and CGK5 mutant derivatives, the Student's *t*-test was performed using GraphPad Prism 6 software (GraphPad, La Jolla, CA, United States). A *P* value less than 0.05 was considered statistically significant.

Results
=======

To examine the effects of the MprF L431F amino acid substitution in an isogenic background, we replaced the chromosomal wild-type *mprF* gene of the DAP-S parental strain CGK5 with the mutant *mprF* gene from the CGK6 DAP-NS strain, creating the new strain CKG5mut. A single base change (from CTT to TTT) causes the L431F mutation in MprF. Furthermore, we generated a reverse mutation complementation construct from CGK5mut, called CGK5mutR, which carries a wild-type *mprF* with a new EcoRV restriction site that can be used to differentiate CGK5mutR from CGK5. CGK5mut and CGK5mutR were verified by PCR and sequencing of the entire *mprF* gene. We then carried out a phenotypic analysis to compare CGK5mut and CGK5mutR against their parental strain CGK5.

The daptomycin MIC of CGK5mut was 6-fold higher (3 μg/ml) compared to that of the wild-type parental strain CGK5 (0.5 μg/ml), a level of increase similar to what we previously reported for DAP-NS clinical isolates ([@B34]). To our surprise, the vancomycin MIC of CGK5mut was also increased compared to CGK5 (3 μg/ml vs. 1.5 μg/ml). The reverse complementation construct, CGK5mutR, showed the same level of susceptibility as CGK5. PAP results showed that, of the three strains, only CGK5mut displayed a hVISA phenotype (**Figure [1A](#F1){ref-type="fig"}**). The bacterial feature that is often associated with DAP-NS and VISA or hVISA strains is increased cell wall thickness ([@B6]; [@B39]). Transmission electron microscopy analysis revealed that CGK5mut has a significantly thicker cell wall (38.09 ± 5.67 nm) than CGK5 (30.65 ± 2.58 nm) and CGK5mutR (25.94 ± 3.75 nm) (*p* \< 0.05) (**Figure [1B](#F1){ref-type="fig"}**). It has also been reported that clinical and *in vitro*-derived *S. aureus* strains exhibiting increased vancomycin MICs grow slower than their progenitors ([@B13]; [@B6]). This phenomenon has been attributed to increased cell wall synthesis at a biological cost to the resistant strains ([@B13]). We also found that CGK5mut (doubling time = 240 ± 9.5 min) grows slower than both CGK5 (doubling time = 158 ± 3.5 min) and CGK5mutR (doubling time = 170 ± 4.2 min) in MHB (**Figure [2](#F2){ref-type="fig"}**).

![Detection of hVISA features. **(A)** Population analysis profile of vancomycin on CGK5 and its mutant derivatives. Overnight cultures of test isolates were serially diluted in Trypticase Soy broth (TSB) and inoculated onto brain heart infusion (BHI) agar plates containing 0 to 8 μg/ml of vancomycin. After 48 h incubation at 35°C, colonies were counted and the results were plotted on a graph. Mu3 (ATCC 700698) and N315 *S. aureus* strains were tested in parallel as hVISA positive and negative controls, respectively. **(B)** Transmission electron microscopy images of CGK5 and its mutant derivatives. Cell wall thickness (in nanometers) was measured at 150,000× magnification. Fifty measurements of equatorially cut cells were taken for calculation of cell wall thickness, and results are expressed as mean ± SD. CGK5, progenitor of CGK5mut; CGK5mut, derivatives of CGK5 with L431F mutation in *mprF*; CGK5mutR, reverse complementation construct of CGK5mut.](fmicb-09-01086-g001){#F1}

![Growth curve of CGK5, CGK5mut, and CGK5mutR in Mueller Hinton II broth (MHB). Overnight fresh cultures of the bacteria were adjusted in 0.85% NaCl to 0.5 McFarland turbidity, then diluted 1:200 in MHB to obtain ∼5 × 10^5^ CFU/ml starting inoculum. The inoculum was dispensed at 120 μl per well in triplicates to a 100-well plate and incubated at 37°C in Bioscreen C MBR. The OD~600~ of each well was read every 30 min for 24 h. The average OD of the blank wells was subtracted from the average of the triplicate test wells at each time point and plotted.](fmicb-09-01086-g002){#F2}

Altered cell membrane charge has been found in some DAP-NS *S. aureus* isolates with point mutations in *mprF* ([@B50]; [@B48]). Cytochrome *c* is a cationic protein that has been used to estimate the relative bacterial cell surface charge of *S. aureus* ([@B43]). We detected a significant increase in unbound cytochrome *c* for CGK5mut (0.676 ± 0.056 mg/ml) compared to CGK5 (0.393 ± 0.058 mg/ml) and CGK5mutR (0.417 ± 0.02 mg/ml) (*p* \< 0.05) (**Figure [3](#F3){ref-type="fig"}**), indicating an increased positive charge density on the cell surface of CGK5mut and suggesting a mechanism by which the L431F mutation of MprF might contribute to daptomycin resistance.

![Binding of cationic cytochrome *c* to CGK5, CGK5mut, and CGK5mutR whole cells. The graph represents the unbound concentrations of cytochrome *c* after 10 min of incubation with CGK5 and CGK5 mutant derivatives. Results are expressed as mean ± SD from three independent experiments. ^∗^*p* \< 0.05.](fmicb-09-01086-g003){#F3}

The mechanism of oxacillin resistance in MRSA is thought to be mainly due to the production of penicillin-binding protein 2a (PBP2a, encoded by the *mecA* gene) with reduced affinity for β-lactams ([@B27]). Although first observed between glycopeptide and β-lactams ([@B55]), the "seesaw" inverse relationship between daptomycin and β-lactam susceptibility has been reported by several groups ([@B42]; [@B34]; [@B60]; [@B39]). We determined the level of PBP2a production in CGK5mut and found it to be comparable to that of CGK5 and CGK5mutR (**Figure [4A](#F4){ref-type="fig"}**).

![PBP2a production and the "seesaw-like" effect. **(A)** Production of penicillin-binding protein 2a (PBP2a) by CGK5 and CGK5 mutant derivatives was measured by Western blot analysis. Membrane protein was extracted from strains grown in medium alone (control) and in oxacillin (0.25 μg/ml)-containing medium with and without 2% NaCl. PBP2a was probed with mouse monoclonal anti-PBP2a antibody (2F6F), and sortase A was used as an internal control by using rabbit polyclonal anti-Sortase A primary antibody. **(B)** Oxacillin MICs of CGK5 and CGK5 mutant derivatives were determined by broth microdilution (BMD) in Mueller Hinton II broth (MHB; containing 2% NaCl or not) from an inoculum of 5 × 10^5^ CFU/ml.](fmicb-09-01086-g004){#F4}

However, concurrent to the increased daptomycin MIC, the oxacillin MIC of CGK5mut decreased to 1 μg/ml from 128 μg/ml in CGK5, as determined by the BMD method in medium without 2% NaCl, whereas CGK5mutR showed a similar MIC as CGK5 (**Figure [4B](#F4){ref-type="fig"}**). Thus, CGK5mut exhibits the "seesaw-like" effect similar to which we and others have previously observed in DAP-NS *in vitro*-selected and clinical *S. aureus* isolates ([@B34]; [@B39],[@B40]). Interestingly, the oxacillin MICs of CGK5, CGK5mut and CGK5mutR were the same (256 μg/ml) in medium containing 2% NaCl (**Figure [4B](#F4){ref-type="fig"}**). Therefore, we further measured the level of PBP2a of these strains grown in oxacillin (0.25 μg/ml) containing medium with and without 2% NaCl. The level of PBP2a of CGK5mut showed a marked reduction after exposure to oxacillin, and 2% NaCl counteracted this effect (**Figure [4A](#F4){ref-type="fig"}**).

Mutation of *mprF* has been shown to impact the expression of *mprF* itself ([@B61]). In addition, VraSR, a two-component regulatory system that plays a major role in cell wall synthesis and is a key player in the cell-wall stress response, has often been implicated in vancomycin and daptomycin resistance ([@B32]; [@B6]; [@B45]; [@B39]). We therefore compared the expression of *mprF* and *vraSR*-related genes in CGK5 and its mutant derivatives by real-time quantitative PCR analysis. We found there was no significant difference in the *mprF* expression among them (**Figure [5](#F5){ref-type="fig"}**). However, significant increases (\>4-fold increase, *P* \< 0.01) in the expression of *vraSR* were seen in CGK5mut compared to CGK5 and CGK5mutR at the 4-h time point. In addition, the expression levels of four examined cell wall synthesis-related genes (*fmtA*, *murZ*, *pbp2*, *sgtB*) were also significantly increased in CGK5mut (\>2∼3-fold increase, *P* \< 0.01) at this time point.

![Transcriptional expression of *mprF* and *vraSR* and cell wall synthesis*-*related genes. Expression of *mprF* and *vraSR*-related genes in CGK5 and CGK5 mutant derivatives was compared by real-time quantitative PCR analysis. Three independent experiments were performed in duplicate at four time points (2, 3, 4, 5 h) and results at the 4-h time point are shown here as mean ± SD. The expression of *ldh1* was used as a negative control. The mRNA expression level of genes from CGK5 was defined as 1. ^∗∗^*p* \< 0.01 when compared to CGK5.](fmicb-09-01086-g005){#F5}

To clarify whether the up-regulation of gene expression in CGK5mut is due to promoter activity, we constructed *mprF* and *vraSR* promoter-reporters. The transcriptional activity of the *mprF* and *vraSR* promoters was compared in CGK5 and its mutant derivatives by using a bioluminescence assay. *mprF* promoter activity among the tested strains showed no obvious differences (**Figure [6A](#F6){ref-type="fig"}**). However, the *vraSR* promoter showed significantly higher promoter activity in CGK5mut compared to the other two strains and the maximum discrepancy was at the 4-h time point (**Figure [6A](#F6){ref-type="fig"}**), indicating that the up-expression of *vraSR* in CGK5mut was mediated by its promoter.

![Transcriptional activity of promoters of CGK5 and its mutant derivatives. Bioluminescence assay was performed to determine the transcriptional level of the **(A)** *mprF* or *vraSR* promoter in CGK5 and CGK5 mutant derivatives (maximal activity at the 4-h time point is shown) and the effect of **(B)** salt concentration on *vraSR* promoter activity in CGK5mut. Data are expressed as relative light units (RLU) from three independent transformants tested in duplicate.](fmicb-09-01086-g006){#F6}

To determine whether the reduced oxacillin MIC of CGK5mut was caused by increased expression of *vraSR*, and how this might be related to the fact that 2% NaCl could restore the oxacillin MIC of CGK5mut to wild-type levels, we examined whether the high salt concentration could inhibit the expression of *vraSR* in CGK5mut. A *vraSR* promoter activity assay showed that NaCl does indeed inhibit *vraSR* promoter activity (**Figure [6B](#F6){ref-type="fig"}**). The effect is dose-dependent and 2% NaCl is the critical concentration for inhibition.

Discussion
==========

Daptomycin is an important last-line agent against serious *S. aureus* infection, particularly in patients with persistent MRSA bacteremia and endocarditis ([@B4]; [@B36]). Daptomycin non-susceptibility in *S. aureus*, albeit still rare, can emerge during treatment and usually in patients with severe deep-seated infections ([@B31]; [@B34]; [@B5]). The mechanism of daptomycin-non-susceptibility is still not fully understood but has been associated with multiple genetic changes on the bacterial chromosome, with single point mutations in the *mprF* gene being the most frequently identified alteration ([@B23]; [@B31]; [@B39]; [@B41]). Although a few hot spots have been associated with daptomycin resistance, such as L826F, S295L, and S337L, there is considerable variation in the locations of the mutations in the MprF polypeptide structure ([@B23]; [@B31]; [@B58]; [@B34]; [@B5]; [@B39]; [@B49]). A study just published by [@B59] investigated the impact of laboratory generated single or dual point mutations within the hot spot loci of *mprF* and found that extra point mutation in *mprF* resulted in diminished characteristics associated with DAP-NS, which may explain why no clinically derived DAP-NS strains contained multiple point mutations within the *mprF* gene.

Our previous study on sequential clinical MRSA isolates from a patient with persistent bacteremia revealed an L431F amino acid substitution in the 3 DAP-NS isolates we characterized ([@B34]). Since this mutation had not been seen in other DAP-NS isolates reported to date, we carried out the present study to verify its contribution to daptomycin resistance. Because some DAP-NS isolates are also vancomycin non-susceptible, and a few DAP-NS isolates (including our own; [@B42]; [@B34]; [@B60]; [@B39]) have been reported to exhibit a reduced oxacillin MIC, we also investigated the effects of this L431F MprF change on vancomycin and oxacillin MICs. The approach we employed differed from those of other studies in that we used a single-base-substitution (from CTT to TTT) method to create the L431F mutant (CGK5mut) from CGK5, the wild-type progenitor of our DAP-NS strains. We also generated a reverse mutant from CGK5mut, CGK5mutR, to verify our findings for CGK5mut. This approach ensured that the strains we tested and compared were isogenic, except for the single nucleotide difference at the site corresponding to codon 431 of MprF (and a mutated silent EcoRV site in CGKmutR which has no effect on the sequence of the polypeptide).

The increased daptomycin MIC observed in CGK5mut confirmed that the L431F missense mutation contributes to daptomycin resistance. We also showed that CGK5mut has reduced binding of cytochrome *c*. Since the L431 amino acid is located in the C-terminal LPG synthase domain of MprF ([@B21]), the daptomycin-non-susceptibility in CGK5mut might be an effect of a reduced PG:LPG ratio ([@B21]; [@B61]). A lower PG:LPG ratio has been shown to reduce the negative charge of the cell membrane ([@B2]; [@B53]), thus diminishing the access of calcium-dependent daptomycin to its cellular target.

Another factor that is commonly associated with daptomycin-non-susceptibility is VraSR ([@B6]; [@B39]), a two-component system that positively regulates the cell wall biosynthesis pathway and is involved in the cell wall stimulon ([@B32]; [@B24]). The VraSR system was originally identified as a key regulator of vancomycin resistance in VISA and hVISA isolates ([@B33]; [@B12]). We found that the expression levels of *vraSR* and several *vraSR*-regulated genes were significantly increased in CGK5mut compared to CGK5 and CGK5mutR. In addition to the increased daptomycin MICs, the vancomycin MIC of CGK5mut was also increased, and population analysis showed that more CGK5mut isolates were able to grow in higher concentrations of vancomycin compared to CGK5 and CGK5mutR. CGK5mut cells also have a thicker cell wall and grow slower than CGK5 and CGK5mutR cells. These cellular features have been associated with both DAP-NS *S. aureus* and hVISA/VISA ([@B6]; [@B56]). The changes in CGK5mut vancomycin MIC and cell wall thickness likely arise from the upregulated *vraSR*-dependent system. But how the L431F mutant protein brings about the increased expression of *vraSR* and the cell wall-related genes is unknown. However, CGK5mut had significant increased *vraSR* promoter activity compared to CGK5 and CGK5mutR using *vraSR* promoter-reporter assay, indicating that the up-expression of *vraSR* in CGK5mut was mediated by its promoter. A previous study observed the mutual presence of both *mprF* point mutations and increased expression levels of *vraSR* in DAP-NS strains compared to their DAP-susceptible counterparts, and hypothesized that both genes were mechanistically linked to the DAP-NS phenotype ([@B39]). However, our results suggest a causal relationship between *mprF* point mutation and increased expression of *vraSR*, which may explain why the daptomycin resistance is often concomitant with vancomycin resistance in clinical isolates. There are a plethora of pathways to heterogeneous and intermediate resistance to vancomycin in *S. aureus* ([@B28]). In addition to VraSR, two other two-component systems, GraSR and WalKR, have also been associated with reduced susceptibility of *S. aureus* to both daptomycin and vancomycin. It has been reported that GraSR also plays an important role in *S. aureus* resistance to cationic antimicrobial peptides via altered expression of *mprF* and *dltABCD* resulting in increased electrostatic repulsion of cationic antimicrobial peptides. GraSR has also been shown to interact with the WalKR system and have significant regulatory overlap ([@B35]; [@B38]; [@B18]; [@B22]). However, we found no significant differences in the expression of *mprF* and *mprF* promoter activity among the tested strains. Therefore, it appears unlikely that reduced susceptibility of CGK5mut to both daptomycin and vancomycin are associated with these two two-component systems.

Although expression of PBP2a (encoded by the *mecA* gene) is thought to play a major role in oxacillin-resistance, several studies have reported that the amount of PBP2a expressed does not correlate with the level of methicillin-resistance ([@B7]; [@B44]; [@B15]), and other auxiliary genes have been reported to be essential for the optimal expression of methicillin-resistance ([@B16]). When we determined the production level of PBP2a in CGK5mut and found it to be comparable to that of CGK5 and CGK5mutR in the normal condition, we thought its "seesaw-like" effect may be caused by other factors. This indicated that the expression of *mecA* gene in CGK5mut was not altered by the *mprF* point mutation. Since the oxacillin MIC of CGK5mut was reduced in medium lacking 2% NaCl, we measured the levels of PBP2a in these strains in the presence of oxacillin with and without 2% NaCl and found that the level of PBP2a production in CGK5mut reduced after exposure to oxacillin and 2% NaCl could abolish this effect. According to the CLSI guideline, 2% NaCl should be added to the medium in determining the oxacillin MIC for staphylococci ([@B11]). Interestingly, our results also showed that the expression of *vraSR* decreased in the presence of 2% NaCl, with a concurrent restoration of oxacillin resistance in CGK5mut, indicating that the effect of upregulation of *vraSR* in CGK5mut could be abolished by adding 2% NaCl. Since the "seesaw" effect has been observed in only a few DAP-NS MRSA isolates ([@B40]), the factors associated with this phenomenon warrant further investigation. However, *mprF* point mutation in CGK5mut only exhibits the "seesaw-like" effect (meaning the seesaw effect was only observed in the absence of NaCl), we speculate that additional mutations at other genes are required to achieve truly "seesaw" effect observed in clinical isolates. In addition, how 2% NaCl counteracts the up-regulation effect of *vraSR* caused by MprF L431F mutation requires further research.

In fact, [@B39] previously observed the phenotype in DAP-non-susceptible strains with upregulation of the two-component regulatory system *vraSR*; however, they did not prove this was caused by the MprF mutation. By contrast, they introduced an overexpression of *vraSR* in DAP-susceptible strains to show a reduction in oxacillin resistance. In their latest study, they found that introducing an overexpression of *vraSR* in DAP-susceptible strains triggering MprF mutation and result in impairment of PrsA chaperone functions, both events are required for β-lactam resistance via PBP2a maturation ([@B51]). It has long been recommended that 2% NaCl (or KCl) be added to the culture medium to reliably detect oxacillin resistance in staphylococci ([@B57]; [@B30]). When salt is placed in solvent, the solid salt dissolves into its component ions, sodium (Na^+^), potassium (K^+^), chloride (Cl^-^), which are the primary ions of electrolytes in physiology. It is plausible to speculate that these ions maintain the phosphorylation state of VraS in respond to *mprF* point mutation and/or β-lactam stimulon to precisely regulate its downstream genes for the generation of resistant phenotype.

Conclusion
==========

The present study demonstrated that a single amino acid substitution (L431F) in the MprF protein contributes to both daptomycin and vancomycin resistance as well as increased oxacillin susceptibility in an isogenic MRSA strain. This point mutation in CGK5 also causes up-expression of *vraSR*. Further studies on the mechanisms contributing to these phenomena may lead to discovery of potential therapeutics against multidrug-resistant staphylococci.
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